CUX2

Across TCGA pan-cancer cohorts, CUX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CUX2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CUX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CUX2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

DLBC, PRAD, and UCEC are the cancer types where CUX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	III,IV	0.657	0.266	.042	3	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CUX2–DLBC (OS)

Open the DLBC breakdown →